Linder S L
Dallas Pediatric Neurology Associates, TX 75243-1708.
Headache. 1994 Nov-Dec;34(10):578-80. doi: 10.1111/j.1526-4610.1994.hed3410578.x.
This study was undertaken to determine whether pediatric patients with migraine without aura who have failed standard outpatient regimens including intravenous dihydroergotamine mesylate (DHE) in conjunction with oral metoclopramide would respond to an inpatient treatment protocol of intravenous DHE and oral metoclopramide. Thirty patients were evaluated in this study which was an open label, retrospective review of treatment. Independent of the duration of the refractory migraine, 80% of the patients responded to the protocol with only minimal side effect. The dose of DHE mesylate ranged from 0.1 to 0.5 mg. The dose of DHE is lower than is typically utilized in standard adult protocols. The patients received an average of five doses of DHE.
本研究旨在确定那些对包括静脉注射甲磺酸二氢麦角胺（DHE）联合口服甲氧氯普胺在内的标准门诊治疗方案无效的无先兆偏头痛儿科患者，是否会对静脉注射DHE和口服甲氧氯普胺的住院治疗方案产生反应。本研究对30例患者进行了评估，这是一项开放标签的治疗回顾性研究。无论难治性偏头痛的病程长短，80%的患者对该方案有反应，且副作用极小。甲磺酸二氢麦角胺的剂量范围为0.1至0.5毫克。DHE的剂量低于标准成人治疗方案中通常使用的剂量。患者平均接受了五剂DHE。
